Last update 01 Nov 2024

TIM1 x Tubulin

Basic Info

Related Targets
TIM1Tubulin

Related

1
Drugs associated with TIM1 x Tubulin
CDX-014
Target
TIM1 x Tubulin
Mechanism
TIM1 inhibitors [+1]
Active Org.
Amgen, Inc.Amgen, Inc. [+1]
Originator Org.
CuraGen Corp.CuraGen Corp.
Active Indication
Renal Cell Carcinoma
Inactive Indication
Metastatic Clear Cell Renal Cell Carcinoma [+4]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with TIM1 x Tubulin
NCT02837991 / TerminatedPhase 1
A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)
100 Clinical Results associated with TIM1 x Tubulin
Login to view more data
100 Translational Medicine associated with TIM1 x Tubulin
Login to view more data
0 Patents (Medical) associated with TIM1 x Tubulin
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free